Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the subject of several other research reports. Mizuho reduced their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $3.65 on Friday. The company has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The business has a 50-day moving average of $3.42 and a two-hundred day moving average of $4.57. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.56.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RVNC. Beryl Capital Management LLC acquired a new stake in Revance Therapeutics during the 4th quarter valued at $18,042,000. Alpine Associates Management Inc. bought a new position in shares of Revance Therapeutics in the third quarter valued at about $21,605,000. Alliancebernstein L.P. lifted its stake in shares of Revance Therapeutics by 7.3% during the 4th quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock worth $10,631,000 after buying an additional 236,641 shares during the last quarter. Magnetar Financial LLC boosted its holdings in shares of Revance Therapeutics by 2.2% during the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after buying an additional 56,174 shares during the period. Finally, State Street Corp grew its stake in Revance Therapeutics by 6.6% in the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after buying an additional 150,323 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.